Moderna's Fourth Quarter 2025 Financial Results: Anticipated Highlights

Moderna, Inc.: Company Overview and Upcoming Earnings

Headquartered in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a biotechnology firm specializing in the research, development, and commercialization of messenger RNA (mRNA) therapies and vaccines. Their work targets a range of conditions, including infectious diseases, cancer, rare disorders, autoimmune issues, and cardiovascular ailments. The company currently holds a market capitalization of $15.9 billion and is set to release its financial results for the fourth quarter of 2025 soon.

Anticipated Financial Results

Analysts are projecting that Moderna will post a diluted loss of $2.79 per share for the upcoming quarter, representing an 11.6% decline compared to the $2.50 loss per share reported in the same quarter last year. Notably, Moderna has exceeded Wall Street’s earnings expectations in each of the past four quarters.

Full-Year and Future Outlook

For the entire fiscal year, experts predict Moderna will report a per-share loss of $7.93, which is an improvement of 10.6% over the $8.87 loss recorded in 2024. Looking ahead to 2026, the loss per share is expected to increase by 13.2% year-over-year, reaching $6.88.

Image source: www.barchart.com

Stock Performance Comparison

Over the past year, Moderna’s stock has risen by 13.2%, trailing the S&P 500 Index’s 16.7% gain. However, it has outperformed the Health Care Select Sector SPDR Fund (XLV), which returned 11.7% during the same period.

Image source: www.barchart.com

Factors Impacting Performance

The company’s recent underperformance is largely attributed to waning demand for COVID-19 vaccines, which has put downward pressure on product revenues. Moderna anticipates ongoing challenges from declining vaccination rates worldwide, especially in the United States, and expects revenues to fall by 20% to 40% as a result.

Recent Earnings Highlights

On November 6, 2025, Moderna’s shares climbed over 3% following the release of its third-quarter results. The company reported a loss per share of $0.51, significantly beating analysts’ expectations of a $2.15 loss. Revenue for the quarter reached $1 billion, surpassing the forecasted $860.1 million. For the full year, Moderna projects revenue between $1.6 billion and $2 billion.

Analyst Ratings and Price Targets

Market sentiment toward Moderna remains cautious, with a consensus “Hold” rating among analysts. Of the 24 analysts covering the stock, two recommend a “Strong Buy,” 19 suggest holding, one rates it as a “Moderate Sell,” and two advise a “Strong Sell.” While Moderna’s current share price is above the average target of $35.15, the highest analyst target of $135 implies a potential upside of 243%.